{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:53:10Z","timestamp":1791910390758,"version":"4.3.4"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118289","type":"journal-article","created":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T13:47:07Z","timestamp":1785073627000},"page":"118289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Glycoprotein nonmetastatic B as a pharmacological target in cancer: structural mechanisms, druggability, and therapeutic translation"],"prefix":"10.1016","volume":"253","author":[{"given":"Haixia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiming","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-7054","authenticated-orcid":false,"given":"Luodan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118289_b0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cac2.12416","article-title":"Tumor microenvironment signaling and therapeutics in cancer progression","volume":"43","author":"Goenka","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.bcp.2026.118289_b0010","doi-asserted-by":"crossref","first-page":"8895","DOI":"10.1038\/s41467-024-53039-1","article-title":"Targeting IRE1\u03b1 reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer","volume":"15","author":"Unal","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118289_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101170","article-title":"Autophagy in cancer development, immune evasion, and drug resistance","volume":"78","author":"Niu","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bcp.2026.118289_b0020","doi-asserted-by":"crossref","first-page":"10030","DOI":"10.1038\/s41467-025-65224-x","article-title":"Regulation of lipoprotein processing by GPNMB in foamy macrophages: potential therapeutic targets for atherosclerosis","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118289_b0025","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/jcp.29107","article-title":"CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF","volume":"235","author":"Li","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2026.118289_b0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.2910600111","article-title":"nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts","volume":"60","author":"Weterman","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13073-025-01553-2","article-title":"Spatial-reprogramming derived GPNMB(+) macrophages interact with COL6A3(+) fibroblasts to enhance vascular fibrosis in glioblastoma","volume":"17","author":"Du","year":"2025","journal-title":"Genome Med."},{"key":"10.1016\/j.bcp.2026.118289_b0040","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2503081122","article-title":"Tumor-expressed GPNMB orchestrates Siglec-9(+) TAM polarization and EMT to promote metastasis in triple-negative breast cancer","volume":"122","author":"Dang Cao","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118289_b0045","doi-asserted-by":"crossref","first-page":"23241","DOI":"10.1038\/srep23241","article-title":"Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K\/Akt and MEK\/ERK pathways via the Na+\/K+-ATPase","volume":"6","author":"Ono","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118289_b0050","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/cas.14872","article-title":"N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC","volume":"112","author":"Han","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118289_b0055","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1038\/onc.2015.8","article-title":"GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin \u03b15\u03b21 for efficient breast cancer metastasis","volume":"34","author":"Maric","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118289_b0060","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118289_b0065","article-title":"An Anti-CD147 Antibody-Drug Conjugate Mehozumab-DM1 is Efficacious against Hepatocellular Carcinoma in Cynomolgus Monkey","volume":"12","author":"Huang","year":"2025","journal-title":"Adv Sci (weinh)"},{"key":"10.1016\/j.bcp.2026.118289_b0070","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.7150\/jca.92661","article-title":"GPNMB Expression Associates with Inferior Prognosis in patients with Small Cell Lung Cancer","volume":"15","author":"Liu","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejca.2019.08.015","article-title":"Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the Children's Oncology Group","volume":"121","author":"Kopp","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.108998","article-title":"GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt\/\u03b2-catenin signaling pathway","volume":"710","author":"Wang","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2026.118289_b0085","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/pbc.25099","article-title":"Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program","volume":"61","author":"Kolb","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pbc.25688","article-title":"Targeting Glycoprotein NMB with Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma","volume":"63","author":"Roth","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0095","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/eji.200838990","article-title":"The DC-HIL\/syndecan-4 pathway inhibits human allogeneic T-cell responses","volume":"39","author":"Chung","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bcp.2026.118289_b0100","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-18-0330","article-title":"Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL\/GPNMB Antibody Restores the In Vitro Integrity of T Cells from Cancer patients","volume":"25","author":"Kobayashi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118289_b0105","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.cell.2026.06.002","article-title":"AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy","volume":"189","author":"Baker","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118289_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-026-10641-1","article-title":"Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells","author":"Savage","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118289_b0115","article-title":"GPNMB-directed CAR T cell therapy against MiT\/TFE-family fusion-driven solid tumors. Nat","author":"Zemp","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0120","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1016\/j.cell.2026.06.003","article-title":"CAR T targets: AI takes the wheel","volume":"189","author":"Amor","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118289_b0125","article-title":"GPNMB-directed CAR-T cell therapies for solid tumors. Nat","author":"Mount","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0130","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.yexcr.2008.02.006","article-title":"Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function","volume":"314","author":"Abdelmagid","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2026.118289_b0135","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.1074\/jbc.M008539200","article-title":"Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans","volume":"276","author":"Shikano","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118289_b0140","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0968-0004(91)90096-E","article-title":"Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif","volume":"16","author":"D'Souza","year":"1991","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.bcp.2026.118289_b0145","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.4049\/jimmunol.179.9.5778","article-title":"Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation","volume":"179","author":"Chung","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118289_b0150","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/pcmr.12084","article-title":"The PKD domain distinguishes the trafficking and amyloidogenic properties of the pigment cell protein PMEL and its homologue GPNMB","volume":"26","author":"Theos","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bcp.2026.118289_b0155","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.1096\/fj.202000651","article-title":"Glycoprotein nonmetastatic melanoma protein B: a key mediator and an emerging therapeutic target in autoimmune diseases","volume":"34","author":"Tsou","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2026.118289_b0160","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/cas.14076","article-title":"Role of the kringle-like domain in glycoprotein NMB for its tumorigenic potential","volume":"110","author":"Xie","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118289_b0165","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-05-2797","article-title":"Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme","volume":"12","author":"Kuan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118289_b0170","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1096\/fj.09-151019","article-title":"Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein","volume":"24","author":"Hoashi","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2026.118289_b0175","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminoncol.2017.10.013","article-title":"LAMPs: Shedding light on cancer biology","volume":"44","author":"Alessandrini","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bcp.2026.118289_b0180","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1111\/cas.15090","article-title":"Glycoprotein non-metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation","volume":"112","author":"Wang","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118289_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012093","article-title":"ADAM10 releases a soluble form of the GPNMB\/Osteoactivin extracellular domain with angiogenic properties","volume":"5","author":"Rose","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118289_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042064","article-title":"Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles","volume":"7","author":"Epple","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118289_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119208","article-title":"Extracellular vesicles from GPNMB-modified bone marrow mesenchymal stem cells attenuate bone loss in an ovariectomized rat model","volume":"272","author":"Huang","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2026.118289_b0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12989-023-00543-9","article-title":"Single-cell transcriptome sequencing-based analysis: probing the mechanisms of glycoprotein NMB regulation of epithelial cells involved in silicosis","volume":"20","author":"Yang","year":"2023","journal-title":"Part. Fibre Toxicol."},{"key":"10.1016\/j.bcp.2026.118289_b0205","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.72.121801.161800","article-title":"Signals for sorting of transmembrane proteins to endosomes and lysosomes","volume":"72","author":"Bonifacino","year":"2003","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.bcp.2026.118289_b0210","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1158\/0008-5472.CAN-18-0599","article-title":"Glycoprotein nmb is Exposed on the Surface of Dormant Breast Cancer Cells and Induces Stem Cell-like Properties","volume":"78","author":"Chen","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118289_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aak9397","article-title":"The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB","volume":"10","author":"Okita","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bcp.2026.118289_b0220","doi-asserted-by":"crossref","first-page":"13932","DOI":"10.18632\/oncotarget.7323","article-title":"Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells","volume":"7","author":"Oyewumi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118289_b0225","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1158\/2159-8290.CD-25-1907","article-title":"A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer","volume":"16","author":"Zhu","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118289_b0230","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-25-1663","article-title":"GPNMB Drives Brain Metastasis by Sculpting a Pathologic Endothelial-Immune Interactome","volume":"16","author":"Liu","year":"2026","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118289_b0235","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-026-00965-1","article-title":"GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization","author":"Zhang","year":"2026","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.bcp.2026.118289_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2026.04.033","article-title":"Secreted GPNMB enhances uptake of fibrillar alpha-synuclein in a non-cell-autonomous process that can be blocked by anti-GPNMB antibodies","author":"Carceles-Cordon","year":"2026","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2026.118289_b0245","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41423-020-0501-0","article-title":"The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33","volume":"18","author":"Liguori","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bcp.2026.118289_b0250","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118289_b0255","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.118289_b0260","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.yexcr.2017.07.005","article-title":"The laminin-derived peptide C16 regulates GPNMB expression and function in breast cancer","volume":"358","author":"Smuczek","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2026.118289_b0265","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-023-05608-3","article-title":"CCN3\/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer","volume":"14","author":"Son","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118289_b0270","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/cas.16419","article-title":"GPNMB is a novel binding partner of FGFR1 that affects tumorigenic potential through AKT phosphorylation in TNBC","volume":"116","author":"Elhinnawi","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118289_b0275","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1038\/s41388-019-0793-7","article-title":"GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K\/AKT\/mTOR pathway signaling and \u03b2-catenin activity","volume":"38","author":"Maric","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118289_b0280","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/cas.15331","article-title":"Tumor endothelial cell-induced CD8(+) T-cell exhaustion via GPNMB in hepatocellular carcinoma","volume":"113","author":"Sakano","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118289_b0285","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114060","article-title":"GPNMB(+) Gal-3(+) hepatic parenchymal cells promote immunosuppression and hepatocellular carcinogenesis","volume":"42","author":"Meng","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2026.118289_b0290","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gutjnl-2024-331903","article-title":"Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma","volume":"74","author":"Chen","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2026.118289_b0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/gutjnl-2024-332934","article-title":"FTO\/m6A\/GPNMB axis: a novel promising target for hepatocellular carcinoma (HCC) treatment?","volume":"74","author":"Heinrich","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.bcp.2026.118289_b0300","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ncb3295","article-title":"The LINK-A lncRNA activates normoxic HIF1\u03b1 signalling in triple-negative breast cancer","volume":"18","author":"Lin","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118289_b0305","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12672-024-01382-6","article-title":"Identification of GPNMB in endometrial cancer based on pan-cancer analysis and in vitro validation","volume":"15","author":"Tuo","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bcp.2026.118289_b0310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40478-024-01754-7","article-title":"Tumor associated microglia\/macrophages utilize GPNMB to promote tumor growth and alter immune cell infiltration in glioma","volume":"12","author":"Yalcin","year":"2024","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.bcp.2026.118289_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104239","article-title":"Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM","volume":"83","author":"Xiong","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.118289_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110972","article-title":"Lactic acid-induced M2-like macrophages facilitate tumor cell migration and invasion via the GPNMB\/CD44 axis in oral squamous cell carcinoma","volume":"124","author":"Lin","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118289_b0325","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1002\/jcp.29177","article-title":"Transcriptome analysis reveals GPNMB as a potential therapeutic target for gastric cancer","volume":"235","author":"Ren","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2026.118289_b0330","first-page":"3034","article-title":"GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K\/Akt\/mTOR signaling pathway","volume":"39","author":"Jin","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2026.118289_b0335","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610450","article-title":"GPNMB-Positive Cells in Head and Neck Squamous Cell Carcinoma-their Roles in Cancer Stemness, Therapy Resistance, and Metastasis","volume":"28","author":"Kawasaki","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.bcp.2026.118289_b0340","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1186\/s12885-018-4903-7","article-title":"GPNMB methylation: a new marker of potentially carcinogenic colon lesions","volume":"18","author":"Ashktorab","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0345","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-026-04466-6","article-title":"Immunohistochemical expression of GPNMB in TFEB-rearranged and TFEB-amplified renal cell carcinomas","author":"Pivovarcikova","year":"2026","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bcp.2026.118289_b0350","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/his.70026","article-title":"GPNMB immunohistochemistry is a useful ancillary tool for the diagnosis of pulmonary lymphangioleiomyomatosis","volume":"88","author":"Szalai","year":"2026","journal-title":"Histopathology"},{"key":"10.1016\/j.bcp.2026.118289_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2026.106192","article-title":"GPNMB immunohistochemistry distinguishes diagnostically challenging cases of lymphangioleiomyomatosis from other mesenchymal neoplasms presenting with cystic lung metastases","volume":"176","author":"Ji","year":"2026","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bcp.2026.118289_b0360","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","article-title":"Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation","volume":"10","author":"Mas-Moruno","year":"2010","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.bcp.2026.118289_b0365","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/jcb.25175","article-title":"Chondroitin Sulfate-E Binds to both Osteoactivin and Integrin \u03b1V\u03b23 and Inhibits Osteoclast Differentiation","volume":"116","author":"Miyazaki","year":"2015","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bcp.2026.118289_b0370","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1021\/cb300255p","article-title":"Fine-tuning multiprotein complexes using small molecules","volume":"7","author":"Thompson","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118289_b0375","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrd.2016.29","article-title":"Small molecules, big targets: drug discovery faces the protein-protein interaction challenge","volume":"15","author":"Scott","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2026.118289_b0380","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118289_b0385","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nprot.2016.051","article-title":"Computational protein-ligand docking and virtual drug screening with the AutoDock suite","volume":"11","author":"Forli","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bcp.2026.118289_b0390","doi-asserted-by":"crossref","first-page":"17863","DOI":"10.1073\/pnas.1420645111","article-title":"Metal ion and ligand binding of integrin \u03b15\u03b21","volume":"111","author":"Xia","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118289_b0395","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118289_b0400","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jim.2017.07.009","article-title":"Long-term direct visualization of passively transferred fluorophore-conjugated antibodies","volume":"450","author":"Schneider","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bcp.2026.118289_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118289_b0410","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.118289_b0415","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118289_b0420","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","article-title":"Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design","volume":"181","author":"Trail","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118289_b0425","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1600-0625.2008.00830.x","article-title":"Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte\/keratinocyte adhesion in a RGD-dependent fashion","volume":"18","author":"Tomihari","year":"2009","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bcp.2026.118289_b0430","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.4049\/jimmunol.178.10.6557","article-title":"Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses","volume":"178","author":"Ripoll","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2026.118289_b0435","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14712598.2012.642357","article-title":"The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer","volume":"12","author":"Keir","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.bcp.2026.118289_b0440","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-09-1611","article-title":"Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer","volume":"16","author":"Rose","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118289_b0445","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.2014.56.2959","article-title":"EMERGE: a Randomized phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer","volume":"33","author":"Yardley","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118289_b0450","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40259-014-0085-2","article-title":"Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE)","volume":"28","author":"Vaklavas","year":"2014","journal-title":"BioDrugs"},{"key":"10.1016\/j.bcp.2026.118289_b0455","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1200\/JCO.2013.52.5683","article-title":"Phase I\/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer","volume":"32","author":"Bendell","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118289_b0460","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41523-021-00244-6","article-title":"Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (\u201cMETRIC\u201d): a randomized multicenter study","volume":"7","author":"Vahdat","year":"2021","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0465","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41388-022-02206-z","article-title":"HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin","volume":"41","author":"Biondini","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118289_b0470","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molonc.2008.02.002","article-title":"Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate","volume":"2","author":"Qian","year":"2008","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bcp.2026.118289_b0475","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2013.54.8115","article-title":"Phase I\/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma","volume":"32","author":"Ott","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118289_b0480","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/cncr.31892","article-title":"A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma","volume":"125","author":"Ott","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0485","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.05.010","article-title":"Targeting GPNMB with glembatumumab vedotin: current developments and future opportunities for the treatment of cancer","volume":"179","author":"Rose","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118289_b0490","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.2217\/fon-2018-0131","article-title":"Antibody-drug conjugates in triple negative breast cancer","volume":"14","author":"Tray","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.bcp.2026.118289_b0495","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1172\/JCI29906","article-title":"Myeloid suppressor cells regulate the adaptive immune response to cancer","volume":"116","author":"Frey","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2026.118289_b0500","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1021\/acs.molpharmaceut.3c00173","article-title":"Human Antibody V(H) Domains Targeting GPNMB and VCAM-1 as Candidate Therapeutics for Cancers","volume":"20","author":"Chu","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2026.118289_b0505","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ijc.25645","article-title":"Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas","volume":"129","author":"Kuan","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118289_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108199","article-title":"Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression","volume":"101","author":"Xu","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118289_b0515","first-page":"115","article-title":"Approach to the Triple negative Breast Cancer in New Drugs Area","volume":"10","author":"Mirzania","year":"2016","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.bcp.2026.118289_b0520","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s43587-021-00151-2","article-title":"Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice","volume":"1","author":"Suda","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.bcp.2026.118289_b0525","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/jb\/mvae091","article-title":"Targeting senescent cells for the treatment of age-associated diseases","volume":"177","author":"Suda","year":"2025","journal-title":"J. Biochem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:25:31Z","timestamp":1791908731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":105,"alternative-id":["S0006295226006283"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118289","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycoprotein nonmetastatic B as a pharmacological target in cancer: structural mechanisms, druggability, and therapeutic translation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118289","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118289"}}